The glucose monitoring market includes all the different devices and drugs used across the patient journey. To deliver appropriate insulin dosing, glucose monitoring is crucial. While new solutions such as non-invasive glucose monitoring are emerging, blood glucose monitoring (BGM) and continuous glucose monitoring (CGM) still dominate the market. CGMs emerged as a response to this demand, providing continuous, or near continuous glucose measurements in non-blood samples. However, this often translates into inaccuracies given the time lag between glucose concentrations in blood and the intersticial fluid, requiring calibration with a BGM. Despite being painless, using a CGM requires wearing a disposable sensor attached to the patient's skin, which is deemed a source of inconvenience by some prescribers and patients. Additionally, these devices are significantly more expensive than traditional options.
GLUMON is a glucose-monitoring device currently under development that performs non-invasive measurements of glucose with improved accuracy and reproducibility. In addition, it avoids any skin damage thanks to its novel optothermal technology, based on layer selection. Moreover, no consumables are needed to operate, reducing the high environmental and economic impact of conventional solutions while simplifying the measurement process.
Key needs for further uptake and success:
a) demonstration and validation studies
b) miniaturization
c) further market research
d) additional investment
e) IP management
f) regulatory and compliance framework
